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OBJECTIVE—This study investigated the acute effects of treat-
ment with vildagliptin on dipeptidyl peptidase-4 (DPP-4) activity,
glucagon-like peptide 1 (GLP-1) concentration, pancreatic hor-
mone levels, and glucose metabolism. The primary aims were to
determine the effects of DPP-4 inhibition on GLP-1 clearance and
on hepatic glucose uptake.
RESEARCH DESIGN AND METHODS—Fasted conscious
dogs were studied in the presence (n  6) or absence (control,
n  6) of oral vildagliptin (1 mg/kg). In both groups, GLP-1 was
infused into the portal vein (1 pmol  kg
1  min
1) for 240 min.
During the same time, glucose was delivered into the portal vein
a t4m g kg
1  min
1 and into a peripheral vein at a variable rate
to maintain the arterial plasma glucose level at 160 mg/dl.
RESULTS—Vildagliptin fully inhibited DPP-4 over the 4-h ex-
perimental period. GLP-1 concentrations were increased in the
vildagliptin-treated group (50  3 vs. 85  7 pmol/l in the portal
vein in control and vildagliptin-treated dogs, respectively; P 
0.05) as a result of a 40% decrease in GLP-1 clearance (38  5 and
22  2m l kg
1  min
1, respectively; P  0.05). Although
hepatic insulin and glucagon levels were not signiﬁcantly altered,
there was a tendency for plasma insulin to be greater (hepatic
levels were 73  10 vs. 88  15 U/ml, respectively). During
vildagliptin treatment, net hepatic glucose uptake was threefold
greater than in the control group. This effect was greater than
that predicted by the change in insulin.
CONCLUSIONS—Vildagliptin fully inhibited DPP-4 activity, re-
duced GLP-1 clearance by 40%, and increased hepatic glucose
disposal by means beyond the effects of GLP-1 on insulin and
glucagon secretion. Diabetes 58:243–249, 2009
G
lucagon-like peptide 1 (GLP-1) is a gut-derived
hormone shown to enhance glucose-dependent
insulin secretion, suppress inappropriately high
glucagon secretion, slow gastric emptying, and
reduce food intake (1). In some type 2 diabetic patients,
GLP-1 levels are reduced, and elevation of GLP-1 by
continuous infusion of the peptide leads to reductions in
fasting glucose, postprandial glucose excursions, and A1C
(2). The therapeutic potential of GLP-1 is limited, however,
because it is rapidly inactivated by dipeptidyl peptidase-4
(DPP-4) (3,4).
Vildagliptin is an orally effective selective DPP-4 inhibi-
tor. In diabetic patients, vildagliptin improved glycemic
control, increased the plasma insulin–to–glucagon mo-
lar ratio, and reduced A1C levels (5,6). During a meal
tolerance test, it augmented insulin secretion and de-
creased glucagon release, resulting in enhanced sup-
pression of endogenous glucose production compared
with placebo (7).
Ingested glucose and endogenously secreted GLP-1 are
released from the gut into the hepatic portal vein, which
then perfuses the liver. Typically, studies have investigated
the effects of DPP-4 inhibition after a meal, when GLP-1
secretion is increased. In the present study, GLP-1 and
glucose were infused directly into the hepatic portal vein
in the presence or absence of DPP-4 inhibition. The ﬁrst
aim was to examine the effect of vildagliptin on GLP-1
clearance under these carefully controlled conditions. In
addition, although GLP-1 can increase glucose disposal by
stimulation of insulin secretion, the hormone has been
suggested to affect glucose metabolism by actions over
and above its effects on the pancreas. Therefore, the
second aim of this study was to investigate the effect of
DPP-4 inhibition on glucose disposal, in particular by the
liver.
RESEARCH DESIGN AND METHODS
Experiments were conducted on 12 healthy, conscious, 18-h–fasted dogs
(20–27 kg). Before the study, they were fed a standard chow diet once a day,
and water was provided ad libitum. The surgical facility met the standards
published by the American Association for the Accreditation of Laboratory
Animal Care, and the protocols were approved by the Lovelace Respiratory
Research Institute Institutional Animal Care and Use Committee before the
start of the study. All dogs underwent a laparotomy 3 weeks before the
experiment to implant infusion catheters into the jejunal and splenic veins.
Sampling catheters were implanted into the hepatic portal vein, the left
hepatic vein, and the left femoral artery. Ultrasonic ﬂow probes (Transonic
Systems, Ithaca, NY) were placed around the hepatic and right iliac arteries
and the portal vein, as described previously (8). Intraportal catheters (splenic
and jejunal) were used for the infusion of glucose (Baxter Healthcare,
Deerﬁeld, IL) and GLP-1 (Bachem, King of Prussia, PA). Each animal was used
only once.
On the day of the study, intravenous catheters were placed into a leg vein
for glucose delivery. Each experiment consisted of a basal period (40 to 0
min) and an experimental period (0–240 min). Vildagliptin (1 mg/kg) or
vehicle (sterile water; control) was administered via stomach gavage at 20
min. Vildagliptin was well tolerated by all animals. At 0 min, constant portal
infusions of glucose (4 mg  kg
1  min
1) and GLP-1 (1 pmol  kg
1  min
1)
were started, and glucose was infused into a peripheral vein to maintain
arterial plasma glucose at 160 mg/dl.
Blood sampling and analytical procedures. Blood samples were collected
from the femoral artery and the hepatic portal and hepatic veins. Hematocrit;
plasma glucose, glucagon, insulin, cortisol, and GLP-1; and blood alanine,
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DIABETES, VOL. 58, JANUARY 2009 243lactate, and glycerol concentrations were determined as previously described
(8). Hepatic blood ﬂow was measured using ultrasonic ﬂow probes and a
Transit-time Perivascular Flow Meter (model T403; Transonic Systems,
Ithaca, NY) as described elsewhere (8). DPP-4 activity was measured in
plasma samples using 7-amino-4-methylcoumarin (AMC; cat. no. Q-1025;
Bachem) as standard and H-Gly-Pro-AMC.HBr (cat. no. I-1225; Bachem) as
substrate. Five microliters of plasma was incubated with 15 l 100 mol/l
substrate for 20 min, and absorption was measured at excitation/emission
wavelength of 360 nm/460 nm with a spectrophotometer. The DPP-4 activity is
expressed as mU/ml where mU  nmol/min.
Data analysis. Net hepatic substrate balance (NHB) was calculated with the
arterial-venous difference method as NHB  loadout  loadin, where loadout 
H  HF and loadin  (A  AF)  (P  PF), in which H, A, and P are the
substrate concentrations in the hepatic vein, femoral artery, and hepatic
portal vein blood or plasma, respectively, and HF, AF, and PF are the blood or
plasma ﬂows in the hepatic vein, hepatic artery, and portal vein, respectively,
as determined by the ultrasonic ﬂow probes. Using this calculation, a positive
value represents net output by the liver, and a negative value represents net
hepatic uptake. For glucose balance calculations, glucose concentrations
were converted from plasma to blood values using previously published
correction factors (9). Blood glucose concentrations were used for the
calculation of net glucose balance because the use of whole-blood glucose
ensures accurate balance measurements regardless of the characteristics of
glucose entry into the erythrocyte. Nonhepatic glucose uptake was calculated
as the glucose infusion rate (GIR) plus net hepatic glucose balance, with changes
in the glucose mass accounted for when deviations from steady-state were
present (10–12). The approximate substrate levels in plasma entering the liver
sinusoids were determined using the formula [A  (AF/HF)  P  (PF/HF)],
where hormone concentrations and ﬂow are abbreviated as previously described.
GLP-1 clearance was determined by dividing the hormone infusion rate by its
arterial concentration after the basal GLP-1 level was subtracted.
Statistical analysis. Data are presented as means  SEM. Between-group
differences were analyzed with two-way ANOVA, and univariate F tests were
used for post hoc comparisons (SigmaStat; SPSS). One-way ANOVA was used
for comparisons of mean data and area under the curve. Statistical signiﬁ-
cance was accepted at P  0.05.
RESULTS
After oral administration of vildagliptin, the arterial and
portal vein plasma DPP-4 activities remained fully sup-
pressed over the 4-h experimental period (Fig. 1; P  0.05).
As a result of portal vein GLP-1 infusion, the plasma GLP-1
levels in the control group increased from 2  1t o3 0 3
pmol/l in the artery and 3  1t o5 0 3 pmol/l in the portal
vein (basal period to average of the last 3 h of the
experimental period; Fig. 2). The rise in GLP-1 was greater
in the vildagliptin-treated group, increasing in the artery
and portal vein, respectively, from 3  1t o5 1 5 and 4 
2t o8 5 7 pmol/l (P  0.05). Whole-body GLP-1 clearance
rates were 38  5 and 22  2m l kg
1  min
1 during the
last 3 h in the control and vildagliptin-treated groups,
respectively (P  0.05).
Glucose was infused to increase the fasting arterial
plasma glucose level from 105 to 160 mg/dl in both
groups (Fig. 3). The intraportal GIR was 4 mg  kg
1 
min
1 in both groups. To maintain the clamp, additional
glucose had to be infused into a peripheral vein in both
the control (6.1  1.2 mg  kg
1  min
1) and vildagliptin-
treated (8.6  1.5 mg  kg
1  min
1; P  0.05) groups
(Fig. 3).
In response to the rise in the plasma glucose level, in the
control group, the plasma insulin increased from 7  1t o
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FIG. 1. Arterial and portal plasma DPP-4 activity in conscious dogs
during the basal (40 to 0 min) and experimental (0–240 min) periods
treated with vehicle (E) or vildagliptin (f) (means  SE; n  6 per
group; *P < 0.05).
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FIG. 2. Arterial and portal plasma GLP-1 levels in conscious dogs
during the basal (40 to 0 min) and experimental (0–240 min) periods
treated with vehicle (E) or vildagliptin (f) (means  SE; n  6 per
group; *P < 0.05).
0
100
200
300
-40 0 30 60 90 120 150 180 210 240
0
2
4
6
8
10
12
Control  (n=6)
Vildagliptin  (n=6)
TIME  ( Min )
ARTERIAL
PLASMA
GLUCOSE
( mg/dl )
PERIPHERAL
GLUCOSE
INFUSION
RATE
( mg/kg/min )
Vildagliptin (1 mg/kg)
* * *
FIG. 3. Arterial plasma glucose level and peripheral GIR in conscious
dogs during the basal (40 to 0 min) and experimental (0–240 min)
periods treated with vehicle (E) or vildagliptin (f) (means  SE; n 
6 per group; *P < 0.05). Glucose was infused into the portal vein at 4
mg  kg
1  min
1 in both groups during the experimental period.
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244 DIABETES, VOL. 58, JANUARY 200926  4 U/ml in the artery and from 17  3t o7 3 10
U/ml in the hepatic sinusoids (increases of 4.1- and
4.3-fold, respectively, from the basal period to the last 3 h;
Fig. 4). The rise in insulin in the vildagliptin-treated group
tended to be larger (6  1t o3 6 8 and 17  3t o8 8 15
U/ml; 5.5- and 5.4-fold), although they were not signiﬁ-
cantly different from the changes in the control group. The
elevations in the arterial plasma C-peptide levels were not
signiﬁcantly different between groups, increasing in the
control group from 0.45  0.04 to 1.27  0.09 ng/ml
(2.9-fold) and in the vildagliptin-treated group from 0.39 
0.04 to 1.40  0.20 ng/ml (3.6-fold) during the two periods,
respectively (Fig. 5). Hepatic sinusoidal plasma glucagon
levels decreased to similar values in the two groups; from
59  11 to 23  4 and 43  3t o2 3 4 pg/ml in the control
and vildagliptin-treated groups, respectively (Fig. 5). The
hepatic plasma insulin–to–glucagon molar ratios were not
signiﬁcantly different (72  10 and 86  14 in the control
and vildagliptin-treated groups, respectively) during the
l a s t3ho ft h estudy.
After a meal, glucose uptake by the liver is stimulated by
increased glucose and insulin levels in the blood. There-
fore, in response to the increases in hepatic glucose load,
portal vein insulin–to–glucagon molar ratio, and plasma
GLP-1 level, there was a switch in net hepatic glucose
balance in the control group from net output (2.4  0.1 mg
 kg
1  min
1 during the basal period) to net uptake
(0.7  0.1 mg  kg
1  min
1 during the last3ho ft h e
experimental period; Fig. 6). In the vildagliptin-treated
group, there was a greater response to these stimuli such
that the liver switched from net hepatic glucose output of
2.1  0.2 to net hepatic glucose uptake of 2.1  0.5 mg
 kg
1  min
1 (P  0.05). Nonhepatic glucose uptake
(non-HGU; mg  kg
1  min
1) increased from basal by
6.8  1.2 in the control group (2.3  0.2 during the basal
period to 9.1  1.2 during the last 3 h, respectively) and by
8.1  1.4 in the vildagliptin-treated group (from 2.3  0.3
to 10.4  1.4, respectively; Fig. 6). Although the nonhe-
patic response was not signiﬁcantly different between the
two groups, the increases in the rate of glucose uptake by
the liver and nonhepatic tissues were greater with vilda-
gliptin treatment by about the same magnitude (1.2 mg 
kg
1  min
1). After vildagliptin treatment, net hepatic
glucose fractional extraction was threefold greater (0.02 
0.01 vs. 0.06  0.01 in the control and vildagliptin-treated
groups, respectively; Fig. 7; P  0.05), as was the ratio of
net hepatic glucose uptake to the hepatic insulin level
(0.01  0.00 vs. 0.03  0.01 in the two groups, respectively;
Fig. 7; P  0.05) during the last3ho ft h estudy. The ratios
of non-HGU to arterial insulin, on the other hand, were
similar in the two groups (0.38  0.04 vs. 0.35  0.05,
respectively; Fig. 7).
No differences in plasma cortisol (data not shown) were
observed between groups. Free fatty acid and glycerol
levels were 25% lower in the vildagliptin-treated group
during the basal period and tended to remain lower during
the study, but the levels were not signiﬁcantly different
between groups at the end of the experiment (Table 1).
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hepatic balance of blood lactate or alanine (Table 1).
DISCUSSION
In this study, vildagliptin fully inhibited DPP-4 over a 4-h
experimental period. As a result, GLP-1 clearance was
reduced by 40%, and the levels of the hormone in plasma
were increased. Although hepatic insulin and glucagon
levels were not signiﬁcantly altered by treatment with the
DPP-4 inhibitor, there was a tendency for plasma insulin to
be greater. Hepatic glucose disposal was nevertheless
increased by treatment, over and above effects attributable
to a rise in insulin. No such effect was seen on nonhepatic
glucose uptake.
GLP-1 levels in the circulation are regulated primarily by
NH2-terminal cleavage at the position 2 alanine by DPP-4
and by renal elimination, but the kidneys appear to only
account for 10–20% of the degradation of intact GLP-1
(13). To our knowledge, an effect of vildagliptin on renal
GLP-1 clearance is not known. In this study, DPP-4 inhi-
bition resulted in a 70% increase in arterial and portal vein
GLP-1 concentrations, which resulted from a 40% decrease
in GLP-1 whole-body clearance. It should be noted that
GLP-1 clearance was determined by dividing the rate of
intraportal GLP-1 infusion by the change in plasma GLP-1.
Although it is possible that a decrease in endogenous
GLP-1 secretion may have occurred, the basal GLP-1 levels
were low (2–3 pmol/l); therefore, any decrease during the
clamp period would have had only a small effect on the
estimate of clearance. In addition, these results are in line
with previous ﬁndings in type 2 diabetic patients in which
4 weeks of treatment with vildagliptin resulted in a two-
fold or greater increase in the rise in active GLP-1 after
meals (6,14).
GLP-1 has previously been shown to increase (1) or to
have no effect on plasma insulin levels (15,16), and vilda-
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FIG. 7. Net hepatic glucose fractional extraction (A), net hepatic glucose uptake–to–hepatic sinusoidal plasma insulin ratio (B), and nonhepatic
glucose uptake–to–arterial plasma insulin ratio (C) during the last3ho ft h eexperimental period (60–240 min) in conscious dogs treated with
vehicle () or vildagliptin (f) (means  SE; n  6 per group; P < 0.05).
TABLE 1
Plasma free fatty acid levels; arterial blood lactate, alanine, and glycerol levels; and net hepatic balance in 18-h–fasted conscious dogs
during the basal (40 to 0 min) and experimental (0–240 min) periods
Basal
period Experimental period (min)
40 to 0 60 120 180 210 240
Plasma free fatty acid level (mol/l)
Control 924  69 245  54 117  23 115  27 147  48 124  39
Vildagliptin 736  118* 111  23 88  26 71  25 82  31 66  15
Blood glycerol level (mol/l)
Control 97  64 2  92 8  43 1  53 5  63 2  6
Vildagliptin 70  9* 21  4* 24  42 0  51 9  41 6  2
Net hepatic glycerol uptake (mol  kg
1  min
1)
Control 1.7  0.1 0.8  0.2 0.5  0.1 0.6  0.2 0.6  0.2 0.6  0.2
Vildagliptin 1.6  0.3 0.5  0.2 0.5  0.1 0.4  0.2 0.5  0.2 0.3  0.1
Blood lactate level (mol/l)
Control 482  81 534  71 536  89 545  66 593  72 564  59
Vildagliptin 433  87 571  82 535  83 555  63 543  49 551  68
Net hepatic lactate balance (mol  kg
1  min
1)
Control 4.5  0.7 2.4  1.7 1.1  0.8 0.3  1.2 0.7  0.9 1.5  1.1
Vildagliptin 2.3  2.7 5.4  2.4 2.1  1.6 3.2  1.7 2.5  1.7 3.2  1.9
Blood alanine level (mol/l)
Control 289  24 261  23 239  16 230  14 235  16 225  15
Vildagliptin 300  33 275  24 245  13 217  18 221  21 219  24
Net hepatic alanine uptake (mol  kg
1  min
1)
Control 2.2  0.2 1.5  0.2 1.7  0.1 2.1  0.2 2.0  0.1 2.2  0.3
Vildagliptin 2.3  0.4 1.8  0.2 2.0  0.5 2.2  0.2 2.4  0.2 2.5  0.3
Data are means  SE; n  6 per group; *P  0.05.
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effect (6), or to decrease (14) the levels of insulin after a
meal. Although the stimulatory effect of GLP-1 on insulin
secretion is well established (1,18), in some studies, insu-
lin levels increased with GLP-1 treatment as a result of
reduced hepatic insulin clearance (19–22), whereas in
others (23–26), clearance was not affected. In the present
study, the increases in arterial C-peptide levels were
greater in the vildagliptin group compared with the control
group by the same relative magnitude as the increases in
insulin levels that occurred, although none of the differ-
ences were statistically signiﬁcant between groups. Thus,
it appears that any elevation in plasma insulin levels
during vildagliptin treatment was the result of a difference
in insulin secretion, not a decrease in clearance.
The role of GLP-1 on canine insulin secretion is not well
understood. An incretin effect has been clearly shown to
be present in the dog (27), but the role of GLP-1 in this
effect has not been clearly established. It is known that a
pharmacological level of GLP-1 can induce insulin secre-
tion in isolated canine pancreata (28) and islets (29). In
addition, we have shown that a pharmacological dose of
exendin-4 (a GLP-1R agonist) is able to induce insulin
secretion (30), whereas an incretin effect has not been
demonstrated in other studies in the dog when GLP-1
was infused intraportally in physiological amounts
(16,27,31,32). In the present study, we once again did
not observe a signiﬁcant effect of elevated GLP-1 on
insulin secretion, although it is possible that a greater
difference in GLP-1 between groups would have re-
vealed an incretin effect.
Patients with type 2 diabetes often exhibit inappropri-
ately high postprandial glucagon levels, which can be
suppressed by GLP-1 (33) and vildagliptin (7). In the
present study, glucagon decreased to levels that were very
similar in both groups. Because the animals studied were
nondiabetic, pancreatic 	-cell sensitivity to inhibition by
hyperinsulinemia and hyperglycemia may have been max-
imal, even in the absence of drug. In addition, the elevated
concentration of GLP-1 in the vehicle-treated group may
have been sufﬁcient to create the maximal effect of GLP-1
on 	-cell suppression.
Although some studies in the human have not revealed
extrapancreatic effects of GLP-1 (34–37), others have
demonstrated insulin-independent effects, including inhi-
bition of glucose production (38). Stimulation of liver
glucose uptake by GLP-1 has been reported in the dog
(39,40), whereas nonhepatic effects on glucose clearance
have been reported in both dogs and humans (16,41–44).
Recently, it was reported that during a meal tolerance test,
patients with type 2 diabetes treated with vildagliptin
showed greater suppression of endogenous glucose
production (7). This effect was associated with in-
creased plasma insulin and reduced plasma glucagon
concentrations. No signiﬁcant differences in the glucose
disappearance or metabolic clearance rates were noted.
In other recent studies, exenatide (an incretin mimetic)
was shown to increase splanchnic (type 2 diabetes [45])
and hepatic glucose uptake (normal dog [30]). In both
studies, the effect was associated with an increase in
plasma insulin concentration. In another study (normal
dog [31]), exenatide reduced postprandial glycemia
independent of islet hormones and slowing of gastric
emptying.
The present study extends these observations by dem-
onstrating that DPP-4 inhibition, accompanied by in-
creased GLP-1 levels, can increase hepatic glucose
disposal. This occurred without a signiﬁcant difference in
the insulin-to-glucagon molar ratio, although the average
hepatic insulin level in the vildagliptin-treated group was
15 U/ml greater than in the control group. Even though
this difference was not statistically signiﬁcant, small dif-
ferences in insulin can affect hepatic glucose production.
Based on previous insulin dose response experiments
(with intraportal glucose and insulin infusions), a 15
U/ml difference would have increased net hepatic glu-
cose uptake by 0.4 mg  kg
1  min
1 (46). Thus, net
hepatic glucose uptake was 1m g kg
1  min
1 greater
during vildagliptin treatment than would have been pre-
dicted from the difference in plasma insulin levels. Al-
though hepatic glucose production was most likely fully
inhibited in both groups because of the elevations in
glucose and insulin, a difference in suppression of glucose
production could also account for some of the difference
in net hepatic glucose uptake between groups. Neverthe-
less, net hepatic glucose fractional extraction and the ratio
of net hepatic glucose uptake to the insulin level at the
liver were threefold greater during DPP-4 inhibition (Fig.
7). Conversely, the tendency for nonhepatic glucose up-
take to be increased was solely attributable to the prevail-
ing arterial insulin levels (Fig. 7).
DPP-4 inhibition also extends the half-life of gastric
inhibitory polypeptide (GIP). However, because there was
no stimulus for incretin secretion in the present study, GIP
levels presumably remained close to basal. Additional
experiments would have to be performed, however, to
deﬁnitively rule out the possibility that the effects ob-
served in this study were due to differences in GLP-1 levels
and not to changes in the activity of another substrate of
DPP-4. The likelihood that they were attributable to GLP-1
is supported by our earlier studies. In one experiment,
which used a similar design as the present study (no
pancreatic clamp and glucose clamped at 160 mg/dl),
when saline or GLP-1 was infused into the liver via the
portal vein or hepatic artery, plasma insulin and glucagon
levels were not affected by GLP-1 infusion (16). Neverthe-
less, the change from basal net hepatic glucose uptake was
greater with GLP-1 vs. saline infusion by 1–1.5 mg  kg
1 
min
1, although these differences were not statistically
signiﬁcant. In other studies in which hepatic insulin and
glucagon levels were clamped at similar levels between
groups, there was a linear relationship between net he-
patic glucose uptake and the plasma concentration of
GLP-1 (39). Thus, those studies support the present data,
which suggest a dose-dependent increase in net hepatic
glucose uptake.
The effect of vildagliptin treatment on liver glucose
disposal was presumably mediated by the difference in
GLP-1 concentrations between groups. The GLP-1 recep-
tor has been identiﬁed in the hepatic portal vein (47) and
the liver (48,49) and could exert its effect through binding
at either site, although it appears that portal receptors may
not be necessary for the effect (39). Glucose entering the
liver may be directed into glycogen because GLP-1 has
been shown to increase glycogen storage in rat hepato-
cytes (50). Although DPP-4 was maximally inhibited by the
start of the experimental period and the maximal differ-
ence in GLP-1 was present by the ﬁrst sampling point in
that period, the maximal difference in response of the liver
was not apparent until 90 min. This slow onset of action
may reﬂect the time required for the synthesis of glu-
coregulatory proteins in the liver.
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DIABETES, VOL. 58, JANUARY 2009 247In summary, in the nondiabetic, overnight fasted dog,
inhibition of DPP-4 by vildagliptin increased plasma GLP-1
levels by reducing its clearance by 40%. In addition, the
rise in GLP-1 associated with DPP-4 inhibition produced
an augmentation of hepatic glucose utilization that was
not accounted for by the effects of the hormone on the
pancreas.
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